New pill could ease deadly lung pressure condition

NCT ID NCT07441278

Not yet recruiting Disease control Sponsor: NS Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests an oral drug called NS-863 in 177 adults with pulmonary hypertension linked to interstitial lung disease (PH-ILD). Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goal is to see if the drug improves blood vessel resistance in the lungs and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NS-863 (an oral drug)

What this could lead to

If successful, this could point toward a new oral treatment to improve blood flow in the lungs for people with PH-ILD.

What could go wrong

This is an early Phase 2 trial with only 177 participants, so results may not confirm benefit. The drug could also cause side effects or fail to improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary hypertension owing to lung disease and/or hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD)